MiR-137 targets and regulates E2F7 to suppress progression of glioma cells

  • Folia Neuropathol. 2022;60(3):346-354. doi: 10.5114/fn.2022.119697.
Jun Li  1 ,  Jingshun Gu  1 ,  Juntong Wang  1 ,  Aiwu You  1 ,  Yuyan Zhang  1 ,  Guomin Rao  2 ,  Shuang Li  3 ,  Xuehua Ge  1 ,  Kun Zhang  1 ,  Xiaotang Wu  4 ,  Ling Cheng  4 ,  Mengjiao Zhu  4 ,  Dongchun Wang  1
Affiliations
  • 1. The Fourth Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, Hebei, P.R. China.
  • 2. The Fourth Department of Neurology, Tangshan Gongren Hospital, Tangshan, Hebei, P.R. China.
  • 3. Department of Traditional Chinese Medicine, Tangshan Gongren Hospital, Tangshan, Hebei, P.R. China.
  • 4. Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai, P.R. China.
PMID: 36382488 DOI: 10.5114/fn.2022.119697
Abstract

Introduction: The paper aimed to explore the mechanism of miR-137 in modulating Glioma.

Material and methods: qRT-PCR detected miR-137 and E2F7 mRNA expression in cells. The protein expression of E2F7 was measured using Western blot assay. Cell proliferation, scratch healing, transwell and programmed cell death assays were conducted to examine the influences of the genes on the biological function of Glioma cells. The dual-luciferase assay verified the interaction between miR-137 and E2F7.

Results: MiR-137 was lowly expressed in Glioma cells, and E2F7 was highly expressed. MiR-137 suppressed progression and promoted programmed cell death of Glioma cells. MiR-137 could target and negatively regulate E2F7 expression to further accelerate programmed cell death of Glioma cells.

Conclusions: It was found that miR-137 could target E2F7 to restrain cell progression and accelerate programmed cell death of Glioma cells, which is helpful to search for new molecular therapeutic targets for Glioma.

Keywords
E2F7; glioma; malignant progression.; miR-137.
Products